Following today’s publication of the Commission on Human Medicines Isotretinoin Expert Working Group report, which can be found here, the British Association of Dermatologists has published the following statement:

The British Association of Dermatologists is committed to ensuring that patients with severe acne have access to the best possible treatments in the safest way. The Commission on Human Medicines (CHM) has reviewed the available evidence and reached the conclusion that the overall balance of risks and benefits for isotretinoin is favourable as long as patients have all the information they need to make an informed decision and are effectively monitored during and after treatment.

This best practice is already established in many areas, and we welcome the opportunity to provide greater clarity for patients and healthcare professionals regarding what is expected during isotretinoin prescribing.

We are currently working with the MHRA on specific details of how to implement the recommendations as efficiently as possible. This will ensure patients with severe acne, not responding to other treatments, can make an informed decision and can continue to access isotretinoin without unnecessary barriers.